2.92% More Anika Therapeutics Inc (NASDAQ:ANIK) Shares Shorted

May 16, 2018 - By Richard Doty

Anika Therapeutics, Inc. (NASDAQ:ANIK) Corporate Logo

Big Money Sentiment decreased to 1.37 in Q4 2017. It has change of 0.05, from 2017Q3’s 1.42. The ratio is negative due to Anika Therapeutics, Inc. positioning: 12 sold and 45 reduced. 24 funds acquired holdings and 54 increased holdings. Investors holded 12.29 million in 2017Q3 but now own 12.26 million shares or 0.18% less.
Ativo Capital Management Lc owns 19,546 shs or 0.28% of their US capital. State Board Of Administration Of Florida Retirement Systems invested in 7,943 shs or 0% of the stock. Eaton Vance Mngmt reported 0% of its capital in Anika Therapeutics, Inc. (NASDAQ:ANIK). Moreover, Btim has 0.2% invested in Anika Therapeutics, Inc. (NASDAQ:ANIK) for 250,148 shs. Glenmede Na has invested 0% of its capital in Anika Therapeutics, Inc. (NASDAQ:ANIK). 10,303 were reported by Art Advsrs Ltd Limited Liability Company. National Bank Of Montreal Can invested in 0% or 2,781 shs. Vanguard Group Inc holds 0% in Anika Therapeutics, Inc. (NASDAQ:ANIK) or 834,970 shs. Gotham Asset Mgmt Ltd Limited Liability Company has 35,587 shs for 0.03% of their capital. Thrivent Financial For Lutherans holds 9,120 shs or 0% of its capital. Envestnet Asset Mngmt Inc holds 0% or 4,963 shs in its capital. Zurcher Kantonalbank (Zurich Cantonalbank) reported 957 shs or 0% of all its holdings. 13,400 are held by First Quadrant Limited Partnership Ca. Mgmt Va holds 0.89% in Anika Therapeutics, Inc. (NASDAQ:ANIK) or 61,085 shs. First Republic Invest Management accumulated 42,690 shs or 0.02% of the stock.

Change of 2.92% for Anika Therapeutics Inc (NASDAQ:ANIK)’s short interest was showed. FINRA announced short interest of ANIK’s total 1.20 million shares. The 1.17 million previous shares are up with 2.92%. With Average volume 140,800, ANIK’s previous position will take 9 days to restore. Anika Therapeutics Inc float short is 8.36%.

ANIK reached $40.09 during the last trading session after $1.94 change.Anika Therapeutics, Inc. has 470,688 shares volume, 252.83% up from normal. ANIK is uptrending and has moved 15.35% since May 16, 2017. The stock outperformed the S&P500 by 3.80%.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally.The firm is valued at $591.14 million. The firm develops, makes, and commercializes therapeutic products based on its proprietary hyaluronic acid technology.The P/E ratio is 19. The Company’s orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Ratings Coverage

Total analysts of 3 have positions in Anika Therapeutics Inc (NASDAQ:ANIK) as follows: 3 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since December 28, 2017 according to StockzIntelligence Inc Anika Therapeutics Inc has 4 analyst reports. On Wednesday, January 24 the firm has “Overweight” rating by First Analysis given. The stock rating was upgraded by Barrington Research to “Outperform” on Friday, May 4. On Friday, February 23 the firm earned “Market Perform” rating by Barrington Research.

For more Anika Therapeutics, Inc. (NASDAQ:ANIK) news published briefly go to: Benzinga.com, Nasdaq.com, Seekingalpha.com, Benzinga.com or Globenewswire.com. The titles are as follows: “Benzinga’s Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down” published on May 04, 2018, “Mid-Afternoon Market Update: Dow Turns Positive; Anika Therapeutics Shares Fall Following Disappointing Q1 Results” on May 03, 2018, “J&J cost cutting plan may pressure suppliers – Bloomberg” with a publish date: April 17, 2018, “The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap” and the last “Report: Developing Opportunities within AMC Networks, JELD-WEN Holding, Blueprint Medicines, Northwest …” with publication date: May 01, 2018.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.